💡KRAS mutations (G12C &amp; G12S) drive aggressive cancers like NSCLC. Current drugs face resistance, but our findings showed 5 promising FDA-approved drugs via drug repurposing.#CancerResearch
#LungCancer #DrugRepurposing #Innovation
#CancerResearch #LungCancer #DrugRepurposing #Innovation